Omnicell (NASDAQ:OMCL) Stock, Quote.Headers.trade-ideas

Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Guidance

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

ISRG

OMCL

TMDX

Omnicell, Inc. (NASDAQ: OMCL) recently announced Central Med Automation Service, a subscription-based solution.

Omnicell Introduces Central Med Automation Service

Crude-oil-4-logo

Eurozone

Commodities

Intraday Update

ALXO

ATEC

EXAS

MRNA

RDHL

Vintage Wine Estates, Inc. - Common Stock

Crude Oil Moves Lower; Moderna Shares Plunge

wall street chart shutter2

Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July

Omnicell Inc

Analysts' ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.6, along with a high estimate of $44.00 and a low estimate of $30.00. Marking an increase of 25.33%, the current average surpasses the previous average price target of $30.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1724421639_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Omnicell by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omnicell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Omnicell's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Omnicell's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Omnicell's Background</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
<h3>Financial Milestones: Omnicell's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Omnicell faced challenges, resulting in a decline of approximately -7.42% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Omnicell's net margin is impressive, surpassing industry averages. With a net margin of 1.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omnicell's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Omnicell adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 5 Takes On Omnicell

JP Morgan analyst Anne Samuel maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Neutral and raises the price target from $26 to $37.

Price Target

JP Morgan Maintains Neutral on Omnicell, Raises Price Target to $37

Omnicell, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (&quot;CPSCs&quot;) and similar operations.&nbsp;
<h3>About Central Med Automation Service</h3>
Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, scalability and patient safety.
The traditional methods of medication management can lead to multi-vendor environments that may complicate workflows, often creating unnecessary redundancy and increasing chances of error.Pharmacy leaders often lack the capital budgets, resources and expertise necessary to transform their infrastructure and scale it over time. Omnicell&#39;s Central Med Automation Service is designed to help health systems develop and execute a central fill strategy while providing the support necessary to ensure this environment meets the current and future medication management needs.
<h3>Features of Central Med Automation Service</h3>
Central Med Automation Service helps seamlessly integrate enterprise-wide robotics, smart devices and intelligent software with expert services.
Within the Robotics &amp; Smart Devices segment, Central Med Automation Service contains XR2 Automated Central Pharmacy System, which is aimed to improve inventory visibility, efficiency and patient safety. In the software segment, Central Med Automation Service has the Central Pharmacy Manager software, designed to support centralized medication management workflows within a CPSC, including medication ordering, receiving, picking, verifying and restocking.&nbsp;
Additionally, it also comes with an Inventory Optimization Service &mdash;a combination of software and expert services. This solution helps provide enterprise-wide inventory visibility and management of medication par levels, expiration dates and usage patterns delivered through data-rich dashboards.
The expert services include tailored guidance from Omnicell experts and dedicated on-site assistance to operate robotics and smart devices. Omnicell expert services utilize data analytics to deliver operational performance metrics, facilitating informed decision-making and continuous improvement in efficiency.
<h3>More on the News</h3>
Central Med Automation Service&#39;s capabilities can be extended by adding several complementary robotics, smart devices and software tools. These include Omnicell&#39;s suite of pharmacy carousels and packagers, 340B program management software and Central Pharmacy Manager Mobile Workstation.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/db/74860.jpg?v=1510659719" />
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
Per a Grand View Research report, the global medical automation market was valued at $44.44 billion in 2022 and is expected to witness a CAGR of 9.04% from 2023 to 2030. Primary factors driving the market include the adoption of automated instruments by drug discovery departments of pharmaceutical companies, the rise in need for miniaturization, and technological advancements, coupled with the rise in demand for robot-assisted surgeries.
Looking at the market potential, it can be seen that the latest development is well-timed and beneficial for Omnicell&#39;s growth.
<h3>Another Recent Development</h3>
Earlier this year, Omnicell introduced XT Amplify &mdash; a multi-year innovation program that is intended to maximize value for hospitals, health systems and post-acute care facilities that have invested in Omnicell&#39;s XT Automated Dispensing System.
<h3>Price Performance</h3>
Year to date, shares of OMCL have risen 12.1% against the industry&#39;s 10.6% decline.
<h3>Zacks Rank and Key Picks</h3>
Omnicell currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Quest Diagnostics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Intuitive Surgical&#39;s shares have surged 68.3% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 EPS have moved up 48.1% to $1.20 cents in the past 30 days. Shares of the company have soared 153.2% in the past year compared with the industry&#39;s 12.6% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Quest Diagnostics&#39; 2024 EPS have increased 0.3% to $8.88 in the past 30 days. In the past year, shares of HAE have risen 14% compared with the industry&#39;s 21.2% growth.
In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.
<a href="https://www.zacks.com/stock/news/2325052/omnicell-omcl-introduces-central-med-automation-service?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325052">To read this article on Zacks.com click here.</a>

Full-Service, Scalable Solution Designed to Help Health Systems Establish and Continuously Optimize Centralized Medication Management Operations
Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>), a leader in transforming the pharmacy care delivery model, today announced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (CPSCs) and similar operations. Central Med Automation Service is intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, which is expected to enhance inventory visibility, scalability, and patient safety.

Omnicell Announces Central Med Automation Service, A Subscription-Based Solution Designed To Help Health Systems Establish And Continuously Optimize Centralized Medication Management For CPCS And Similar Operations

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and raises the price target from $26 to $30.

Wells Fargo Maintains Equal-Weight on Omnicell, Raises Price Target to $30

B of A Securities analyst Allen Lutz maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and raises the price target from $34 to $44.

B of A Securities Maintains Buy on Omnicell, Raises Price Target to $44

Barclays analyst Stephanie Davis upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Underweight to Equal-Weight and raises the price target from $26 to $39.

Upgrades

Barclays Upgrades Omnicell to Equal-Weight, Raises Price Target to $39

U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday.
The Dow traded down 1.61% to 40,184.39 while the NASDAQ fell 2.77% to 17,111.79. The S&amp;P 500 also fell, dropping, 1.78% to 5,424.16.
Leading and Lagging Sectors Utilities shares gained by 1.5% on Thursday.
In trading on Thursday, information technology shares fell by 4%.
Top Headline Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock dipped more than 20% on Thursday as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
Moderna now projects 2024 net sales of between $3 billion and $3.5 billion from its respiratory franchise versus previous guidance of about $4 billion, citing low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.
Moderna reported second-quarter revenue of $241 million, compared with $344 million a year earlier, beating the consensus of $132.18 million.
Net loss was $1.28 billion, or $3.33 a share, versus a loss of $1.38 billion, or $3.62 a share, a year earlier, surpassing the consensus of $(3.36).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares shot up 80% to $0.69 after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn&#8217;s disease.</li>
<li>Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) got a boost, surging 23% to $56.26&nbsp;after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) shares were also up, gaining 31% to $38.20 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares dropped 41% to $0.0305 after the company announced a bankruptcy filing and a voluntary delisting and SEC deregistration.</li>
<li>Shares of ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) were down 40% to $2.89. The company released topline data from its Phase 2 ASPEN-06 clinical trial.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) was down, falling 29% to $7.15 after the company reported mixed second-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 1.8% to $76.53 while gold traded up 0.3% at $2,481.50.
Silver traded down 1.9% to $28.395 on Thursday, while copper fell 2.8% to $4.0595.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.23%, Germany's DAX fell 2.30% and France's CAC 40 fell 2.14%. Spain's IBEX 35 Index fell 1.9%, while London's FTSE 100 fell 1.01%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.49%, Hong Kong's Hang Seng Index falling 0.23% and S&amp;P BSE Sensex gaining 0.15%.
Economics
<ul>
<li>The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.</li>
<li>Construction spending declined by 0.3% month-over-month to an annual rate of $2,148 billion in June.</li>
<li>U.S. initial jobless claims by 14,000 to 249,000 in the week ending July 27th, beating market estimates of 236,000.</li>
<li>Nonfarm business sector labor productivity increased by 2.3% in the second quarter, compared to a revised 0.4% rise in the prior period.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 500 points on Thursday.
The Dow traded down 1.26% to 40,327.48 while the NASDAQ fell 1.57% to 17,322.26. The S&amp;P 500 also fell, dropping, 1.05% to 5,464.56.
Leading and Lagging Sectors Communication services shares gained by 1.1% on Thursday.
In trading on Thursday, information technology shares fell by 2.3%.
Top Headline The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares shot up 56% to $0.6008 after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn&#8217;s disease.</li>
<li>Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) got a boost, surging 24% to $56.70&nbsp;after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) shares were also up, gaining 28% to $37.29 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares dropped 34% to $0.0342 after the company announced a bankruptcy filing and a voluntary delisting and SEC deregistration.</li>
<li>Shares of ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) were down 37% to $3.0250. The company released topline data from its Phase 2 ASPEN-06 clinical trial.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) was down, falling 23% to $7.80 after the company reported mixed second-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $77.26 while gold traded up 0.7% at $2,489.90.
Silver traded down 1% to $28.655 on Thursday, while copper fell 1.9% to $4.0975.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.23%, Germany's DAX fell 2.32% and France's CAC 40 fell 2.14%. Spain's IBEX 35 Index fell 1.9%, while London's FTSE 100 fell 1.01%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.49%, Hong Kong's Hang Seng Index falling 0.23% and S&amp;P BSE Sensex gaining 0.15%.
Economics
<ul>
<li>The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.</li>
<li>Construction spending declined by 0.3% month-over-month to an annual rate of $2,148 billion in June.</li>
<li>U.S. initial jobless claims by 14,000 to 249,000 in the week ending July 27th, beating market estimates of 236,000.</li>
<li>Nonfarm business sector labor productivity increased by 2.3% in the second quarter, compared to a revised 0.4% rise in the prior period.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

U.S. stocks were lower, with the Dow Jones index falling over 500 points on Thursday.
Shares of Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/08/40100921/air-products-q3-win-eps-surge-and-margin-expansion-set-stage-for-promising-q4">adjusted EPS results</a>.
Air Products reported third-quarter 2024 adjusted EPS of $3.20, up 7% year-over-year, beating the consensus of $3.03. Sales declined 2% YoY to $2.986 billion, missing the consensus of $3.035 billion due to 2% unfavorable currency and 1% lower energy cost pass-through.
Air Products shares jumped 11.4% to $293.82 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares surged 26.2% to $3.9750. Corning and Lumen reached a supply agreement on next-generation fiber-optic cable to support data center AI demands.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) jumped 24.3% to $56.80 after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 22.3% to $35.71 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) climbed 17.8% to $103.22 after the company reported better-than-expected second-quarter sales results.</li>
<li>Clearwater Analytics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NASDAQ">CWAN</a>) gained 17.5% to $22.97 after the company reported better-than-expected second-quarter sales results and issued FY24 revenue guidance above estimates..</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) jumped 15.8% to $9.12.</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) gained 15.1% to $102.48 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Energy Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) gained 14.7% to $16.72 following upbeat quarterly results.</li>
<li>Frontdoor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) gained 14.2% to $45.06 following better-than-expected second-quarter financial results.</li>
<li>Hawkins, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) rose 14.1% to $118.53 following upbeat quarterly results.</li>
<li>Ranpak Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NASDAQ">PACK</a>) gained 12.7% to $8.14 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) rose 12.4% to $24.07 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue guidance above estimates. Additionally, Morgan Stanley and Oppenheimer raised their respective price targets on the stock.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) rose 12.2% to $72.73 after the company reported better-than-expected quarterly financial results..</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 12% to $65.34 following quarterly financial results..</li>
<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) rose 10.6% to $262.60 after the company reported better-than-expected quarterly financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) gained 9.5% to $145.82 after the company reported better-than-expected quarterly financial results.</li>
<li>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) gained 5.8% to $73.46 after the company reported better-than-expected second-quarter adjusted EPS results and raised its FY24 adjusted EPS above estimates. Additionally, the company announced the authorization of a $5 billion share repurchase program..</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose 5.8% to $502.20 following better-than-expected quarterly earnings.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Movers

ACHC

ALNY

APTV

CHRW

CVNA

CWAN

ERII

FTDR

HWKN

LUMN

PACK

SHAK

ZETA

Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday

WIIM

Omnicell shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 guidance above estimates.

Based on strong first half performance and current visibility of the business, the Company is updating the previously provided 2024 annual&nbsp;guidance&nbsp;metrics. For the full year 2024, the Company expects bookings to be between&nbsp;$775 million&nbsp;and&nbsp;$875 million. The Company expects full year 2024 total revenues to be between&nbsp;$1.070 billion&nbsp;and&nbsp;$1.110 billion. The Company expects full year 2024 product revenues to be between&nbsp;$610 million&nbsp;and&nbsp;$630 million, and full year 2024 service revenues to be between&nbsp;$460 million&nbsp;and&nbsp;$480 million. The Company expects full year 2024 technical services revenues to be between&nbsp;$230 million&nbsp;and&nbsp;$240 million, and full year 2024 Advanced Services revenues to be between&nbsp;$230 million&nbsp;and&nbsp;$240 million. The Company expects full year 2024 non-GAAP EBITDA to be between&nbsp;$105 million&nbsp;and&nbsp;$125 million. The Company expects full year 2024 non-GAAP earnings per share to be between&nbsp;$1.20&nbsp;and&nbsp;$1.50&nbsp;per share.

Omnicell Sees FY24 Revenues Between $1.07B-$1.110B Vs. $1.06B Estimate (Prior View: $1.045B-$1.120B) With Adjusted EPS Of $1.20-$1.50 Vs. $1.11 Estimate (Prior View: $0.90 - $1.40)

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.14 by 264.29 percent. This is a 10.53 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $276.79 million which beat the analyst consensus estimate of $255.20 million by 8.46 percent. This is a 7.42 percent decrease over sales of $298.97 million the same period last year.

Omnicell Q2 Adj $0.51 Beats $0.14 Estimate, Sales $276.79M Beat $255.20M Estimate

Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and maintains $38 price target.

Reiteration

Benchmark Reiterates Buy on Omnicell, Maintains $38 Price Target

The table below summarizes Omnicell&#39;s second quarter and full year 2024 guidance outlined above.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Q2 2024
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Bookings
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$750 million - $875 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total Revenues
</td>
<td colspan="1" rowspan="1">
$250 million - $260 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.045 billion - $1.120 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Product Revenues
</td>
<td colspan="1" rowspan="1">
$140 million - $145 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$605 million - $650 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Service Revenues
</td>
<td colspan="1" rowspan="1">
$110 million - $115 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$440 million - $470 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Technical Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Advanced Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP EBITDA
</td>
<td colspan="1" rowspan="1">
$14 million - $20 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$90 million - $120 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Earnings Per Share
</td>
<td colspan="1" rowspan="1">
$0.10 - $0.20
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$0.90 - $1.40
</td>
</tr>
</tbody>
</table>
&nbsp;

Omnicell Reaffirms FY24 Outlook: Adj EPS $0.90-1.40 vs $1.07 Est; Sees Sales $1.045B-1.120B vs $1.06B Est

The table below summarizes Omnicell&#39;s second quarter and full year 2024 guidance outlined above.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Q2 2024
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Bookings
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$750 million - $875 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total Revenues
</td>
<td colspan="1" rowspan="1">
$250 million - $260 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.045 billion - $1.120 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Product Revenues
</td>
<td colspan="1" rowspan="1">
$140 million - $145 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$605 million - $650 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Service Revenues
</td>
<td colspan="1" rowspan="1">
$110 million - $115 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$440 million - $470 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Technical Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Advanced Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP EBITDA
</td>
<td colspan="1" rowspan="1">
$14 million - $20 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$90 million - $120 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Earnings Per Share
</td>
<td colspan="1" rowspan="1">
$0.10 - $0.20
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$0.90 - $1.40
</td>
</tr>
</tbody>
</table>

Omnicell Q2 Outlook: Total Revenues $250M - $260M Vs. $261.88M Estimate, Adj. EPS $0.10-$0.20 Vs. $0.27 Estimate

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.09) by 133.33 percent. This is a 92.31 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $246.150 million which beat the analyst consensus estimate of $236.754 million by 3.97 percent. This is a 15.30 percent decrease over sales of $290.629 million the same period last year.

Omnicell Q1 2024 Adj EPS $0.03 Beats $(0.09) Estimate, Sales $246.150M Beat $236.754M Estimate

Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. &nbsp;
Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to medium-sized companies, Mr. Kuipers brings over 25 years of technology leadership experience to the CFO role at Clover. As the former Executive Vice President and CFO at Omnicell, Inc., a healthcare technology company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>), Mr. Kuipers provided financial leadership and strategic vision, contributing to the company's growth from $485 million to $1.3 billion in revenue. Beyond the CFO function, Mr. Kuipers oversaw various other critical functions, including global supply chain &amp; manufacturing, information technology, international business, corporate development, and M&amp;A, playing a pivotal role in transforming Omnicell into a cloud-based platform and SaaS/Tech-Enabled Services market leader.
Prior to his role at Omnicell, Mr. Kuipers served as the CFO at Quantcast and The Weather Company, where he provided financial leadership driving profitable revenue growth through capital allocation, digital platform development, and global expansion. His extensive background also includes divisional CFO and executive FP&amp;A leadership roles at Yahoo!, Altera Corporation (acquired by Intel), General Electric Company, and Akzo Nobel, where he implemented financial management strategies and operating rigor to drive business execution at scale.
Mr. Kuipers started his career with nearly a decade at Ernst &amp; Young where he focused on financial audits, IPO services, and M&amp;A due diligence for multinational companies. He received a Master's Degree in Economics and Business Administration from the Maastricht University School of Business and Economics, and is a Chartered Accountant in the Netherlands.
"We are thrilled to welcome Peter to Clover as our new Chief Financial Officer," said Andrew Toy, Chief Executive Officer, Clover Health. "His extensive experience as a public company Chief Financial Officer and strong leadership skills make him the perfect fit to lead our finance team as we look to achieve Adjusted EBITDA profitability for 2024, and then embark on our next phase of growth."
In his role as CFO, Kuipers will be responsible for overseeing all financial aspects of the Company, including budgeting, forecasting, financial reporting, and capital management. He will play a pivotal role in driving financial performance and implementing strategies to optimize operational efficiency.
"I am honored to join Clover at such an exciting time in its journey," said Peter Kuipers. "I have always believed in the ability of technology to fundamentally transform an industry and Clover has shown that with its platform, it has a unique approach that can power profitability and growth in a differentiated way. I'm thrilled to be part of the team that will be focused on bringing that capability to care for as many people as possible."

CLOV

Clover Health Appoints Peter Kuipers As Chief Financial Officer, Effective As Of The Day After The Filing Of The Co's Quarterly Report On Form 10-Q For The Quarter-Ended March 31, 2024

Omnicell upgraded at Barclays after earnings-driven rally

Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript

The 1-Minute Market Report August 3, 2024

'Bottom-fishing' ideas within Piper Sandler's universe of stocks

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Omnicell (OMCL – Research Report) today. The company's shares closed yesterday at $42.1...

Omnicell (OMCL) Receives a Buy from Craig-Hallum

In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Omnicell (OMCL – Research Report), with a price target of ...

Piper Sandler Remains a Buy on Omnicell (OMCL)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Omnicell (OMCL – Research Report) today. The company's shares closed yesterday at $45.4...

Craig-Hallum Remains a Buy on Omnicell (OMCL)

Wells Fargo analyst Stan Berenshteyn maintained a Hold rating on Omnicell (OMCL – Research Report) yesterday and set a price target of $30.00. Stan...

Omnicell's Steady Growth and Hold Rating: A Cautious Outlook on Automation Services Expansion

Stan Berenshteyn, an analyst from Wells Fargo, maintained the Hold rating on Omnicell (OMCL – Research Report). The associated price target remains...

Omnicell's Strategic Rebranding and Market Outlook: A Hold Recommendation

In a report released today, Scott Schoenhaus from KeyBanc maintained a Hold rating on Omnicell (OMCL – Research Report). The company's shares close...

Omnicell (OMCL) Receives a Hold from KeyBanc

ACTV

AFMC

AFSM

AKAM

AMPH

ARKG

ARKK

ATNI

AVUV

BAPR

BCRX

BITO

BLOK

DXCM

EPAM

FORM

GLTR

HRMY

INSP

INTC

IVOO

IVOV

JAZZ

JETS

KCCA

KNSL

KRBN

MAGS

MASI

MTCH

MYRG

PCTY

PODD

RGEN

RMBS

SIVR

SKYT

SNBR

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSLY

SSPY

SVAL

SYLD

TMDV

TPHD

TPLC

TPSC

TWLO

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

URNM

USMC

USMF

USVM

UTWO

VEEV

YETI

Press Releases

Omnicell Announces XT Amplify

Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

Omnicell Announces First Quarter 2024 Results

Omnicell to Present at the BofA Securities 2024 Health Care Conference

Omnicell Supports Global Charity Mercy Ships with Pharmacy Technology Donation

Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

Omnicell Announces Second Quarter 2024 Results

EnlivenHealth® and Good Neighbor Pharmacy® Seek to Empower Independent Pharmacies with New Clinical Scope of Practice and Reimbursement Solution

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Omnicell

Omnicell (OMCL) Forecast

Omnicell (NASDAQ:OMCL) Stock, Quote.Headers.trade-ideas